Roth Mkm Lowers OptimizeRx (NASDAQ:OPRX) Price Target to $18.00

OptimizeRx (NASDAQ:OPRX) had its price objective reduced by investment analysts at Roth Mkm from $32.00 to $18.00 in a research report issued on Friday,Benzinga reports. The firm presently has a “buy” rating on the stock. Roth Mkm’s price target indicates a potential upside of 182.57% from the stock’s current price.

Several other brokerages have also issued reports on OPRX. Stifel Nicolaus cut their price objective on shares of OptimizeRx from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday. Citizens Jmp lifted their price target on OptimizeRx from $23.00 to $24.00 and gave the company a “market outperform” rating in a report on Friday, November 7th. Stephens reduced their price target on OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating for the company in a research report on Friday. B. Riley Financial restated a “buy” rating and set a $11.00 price objective (down from $28.00) on shares of OptimizeRx in a research note on Friday. Finally, Weiss Ratings reiterated a “sell (d+)” rating on shares of OptimizeRx in a research note on Monday, December 22nd. Five equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, OptimizeRx has an average rating of “Moderate Buy” and a consensus target price of $17.17.

OptimizeRx Stock Down 15.4%

Shares of OPRX stock traded down $1.16 on Friday, hitting $6.37. The stock had a trading volume of 1,432,824 shares, compared to its average volume of 390,957. The company has a quick ratio of 3.05, a current ratio of 3.05 and a debt-to-equity ratio of 0.20. The business has a 50 day moving average price of $10.63 and a 200 day moving average price of $14.80. The company has a market cap of $118.74 million, a PE ratio of 19.67 and a beta of 1.20. OptimizeRx has a one year low of $3.99 and a one year high of $22.25.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Saturday, January 31st. The company reported $0.51 earnings per share (EPS) for the quarter. OptimizeRx had a net margin of 0.03% and a return on equity of 6.37%. Research analysts anticipate that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

OptimizeRx declared that its Board of Directors has authorized a stock buyback program on Thursday, March 5th that allows the company to buyback $10.00 million in outstanding shares. This buyback authorization allows the company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Institutional Investors Weigh In On OptimizeRx

Large investors have recently modified their holdings of the business. Millennium Management LLC acquired a new position in shares of OptimizeRx during the fourth quarter valued at about $535,000. Inspire Investing LLC acquired a new position in OptimizeRx during the 4th quarter valued at approximately $1,175,000. Engineers Gate Manager LP purchased a new position in shares of OptimizeRx in the fourth quarter worth $228,000. Boothbay Fund Management LLC lifted its stake in shares of OptimizeRx by 53.1% during the fourth quarter. Boothbay Fund Management LLC now owns 73,488 shares of the company’s stock worth $901,000 after buying an additional 25,502 shares during the period. Finally, Bridgeway Capital Management LLC grew its holdings in shares of OptimizeRx by 16.9% during the fourth quarter. Bridgeway Capital Management LLC now owns 69,029 shares of the company’s stock valued at $846,000 after buying an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 76.47% of the company’s stock.

OptimizeRx News Summary

Here are the key news stories impacting OptimizeRx this week:

• Positive Sentiment: Q4 results topped estimates — OPRX reported $0.51 EPS and $32.24M in revenue, beating consensus and highlighting continued revenue growth. This is the fundamental positive underpinning the shares. GlobeNewswire: Press Release
• Positive Sentiment: Board authorized a $10.0M share repurchase (up to ~6.8% of shares), a signal management views the stock as undervalued and a potential support for the share price. RTT News: Buyback
• Neutral Sentiment: Company-hosted earnings call and multiple transcripts are available for investors to assess management commentary and execution plans; useful for judging sustainability of growth and margin outlook. Yahoo Finance: Earnings Highlights
• Neutral Sentiment: Trading experienced repeated LULD pauses (multiple intraday halts) — this indicates elevated volatility and may have contributed to larger intraday moves and volume. (Market notices reported multiple LULD pauses.)
• Negative Sentiment: FY‑2026 revenue guidance of $109M–$114M came in materially below the consensus (~$122M), creating the primary negative catalyst pushing the stock lower as investors reprice forward growth expectations. Seeking Alpha: Guidance
• Negative Sentiment: Stephens cut its price target from $17 to $10 and moved to an “equal weight” rating, sending a clear signal to investors and likely amplifying selling pressure from analysts/quant strategies. Benzinga: Analyst Note

About OptimizeRx

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.